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Two years ago, the National Cancer Institute formed a Task Force' to suggest ways in which the chemical control of the leukemias might be accomplished.
What I am about to say has arisen for the most part from these discussions, and I wish to give to the members of the Task Force most of the credit, but none of the blame for my interpretations of these concepts and data.
One of the first problems in chemical control studied by the Task Force was the value of animal leukemias in predicting drug effects in patients. From a review of mouse and clinical leukemias, it quickly became evident that L1210 mouse leukemia resembled childhood leukemia in many respects. It seemed worth while to use this model to discover how to attain complete chemical control or cure of childhood leukemia. Dr Howard Skipper and his colleagues have examined the L1210 model in great detail (Skipper et al. 1964 ) and have drawn the following four conclusions:
(1) One living leukemic cell injected intraperitoneally into the BDF, mouse eventually kills the host. This confirms and extends earlier (Furth & Kahn 1937 , Goldin et al. 1956 ). Extensive studies have shown that the generation time of the L1210 leukemic cell averages 0 55 day. The lethal number of leukemic cells, approximating one and one-half billion (1 5 x 109) is reached in nineteen days. Since one cell can proliferate to a lethal number, cure can be achieved only when it is possible to kill every leukemic cell in the host.
(2) When the leukemic animal is treated, the percentage of the cell population killed by a given drug is constant for that drug at the particular dosage. Regardless of the size of the cell population, the fractional kill is the same. If a drug will kill 99 9999% (or 6 logs) of cells in vivo, it will not cure any animals with a cell population of a billion (9 logs) but it would cure almost all of animals with ten thousand (4 logs) cells.
(3) There is a relationship between the amount of drug given and the percentage of leukemic cells killed. In studies with single doses of drugs, the higher the dosage the greater the percentage kill. If cure is to result from chronic daily dosage, the percentage kill must be greater than the rate of proliferation (equivalent to quadrupling every twenty-four hours). (4) The above holds true only when drug is distributed to all anatomic compartments of the body containing leukemic cells. In the mouse, when the cell population is above I1 x10, cells escape into the central nervous system, which cannot be reached by most antileukemic drugs. 'Cure' of leukemia presupposes that drug can somehow attack cells in every compartment.
In the extension of the kinetics of L1210 mouse leukemia to the clinic, it was assumed that chemical control or cure requires that the drug should destroy every cell in the host at doses that can be tolerated. In judging the utility of these concepts in human leukemia, it would be helpful to know (a) the size of the cell population when clinical leukemia is present; (b) the generation time of human leukemic cells; (c) the fractional kill of leukemic cells achieved by each antileukemic drug. With this information, it would be possible to calculate what fraction of cells had been killed by drug. It has been estimated (Frei 1964 ) that at the time of clear-cut relapse of childhood leukemia, there is a leukemic cell population of approximately 2 5 x 1012. This was calculated from the fact that 1-0 ml of packed leukemic cells contains 1 x 109 cells, and from estimates made at autopsy of the volumes of marrow, spleen, lymph nodes and blood in a 30 kg child. Frei has assumed that there is no lag phase in regrowth of leukemic cells and that they divide at an exponential rate.
From studies of the rate of increase of leukemic cells in the marrow Frei (1964) estimated that the generation time of leukemic cells in childhood leukemia is four to five days. Clarkson et al. (1964) , in their work with the incorporation of tritiated thymidine into leukemic cells of patients not on treatment, concluded that the generation time averaged four days.
From these rough estimates of number of cells at time of clinical relapse (2-5 x 1012) and of generation time (four days) Frei has calculated the fraction of cells killed by a given drug, from the length of the period between cessation of drug and thl time of relapse. When leukemic children were treated with prednisone to complete remission, the median time of relapse after cessation of drug was sixty days; after vincristine, forty-two days. By back plotting to zero time, it is estimated that at the time of complete remission the children treated with prednisone had 108 cells remaining and those with vincristine 109 cells. Thus, it can be argued that these drugs destroyed 4 logs (99 990%) and 3 logs (99 9 %) of cells respectively. This is a long way from complete destruction of the leukemic cell population. Experience with treatment by other single agents capable of inducing complete remission, e.g. methotrexate, 6-mercaptopurine or cyclophosphamide, suggests that antilcukemic drugs used as single treatment cannot approach complete destruction of the leukemic cell population (Table 1) . The sequential use of the three classic agentsmethotrexate, 6-mercaptopurine, and prednisonehas led to a few quite prolonged survivals (Zuelzer 1964 , Brubaker et al. 1963 ), but these continuous treatment schedules do not penrmit a calculation of the fractional kill of the leukemic cells. Presumably, the drugs were given over long periods in such a way that fractional kill and proliferation of cells balanced one another at populations below 2-5 x10\ . The logic of the model (namely, the greater the percentage kill, the longer the remission and therefore complete kill might mean permanent remission) led to a trial of combinations of the effective agents. With five agents known to produce complete remissions there are thirty-two possible combinations. Since each trial requires several years of observation, Freireich and his colleagues (1964) decided to try combinations of four. The first of these is the so-called VAMP study wherein the patients received full doses of vincristine and prednisone and twothirds full doses of methotrexate and mercaptopurine. The dosage details are as follows:
Vincristine: 2 Mg/m2/week I.V.
Methotrcxate: 20 mg/m2/every four days I.V. Mercaptopurine: 60 mg/m2/day orally Prednisone: 40 mg/m2/day orally The drugs were given in ten-day courses, with a minimum of ten days' rest in between until four to six courses had been given. The therapy took an average of four months. The drugs were then discontinued. Of 17 children with acute lymphocytic leukemia, 15 achieved complete remission in the first course. One died of rapidly advancing leukemia, the other of monilial septicemia. Of the 15 who went on to additional courses, 11 completed the full therapy. Two died of infection and 2 had recurrent leukemia. After cessation of therapy leukemia recurred in 9 patients with a median duration of remission of twenty-one weeks. Two children are still in complete remission 650 days after cessation of drugs. While this is a small group, an approximation to complete destruction of leukemic cells must have been reached in the 2 patients who have remained in complete remission. The 650-day freedom from disease should be compared to the calculated relapse time of 164 days from a fractional (99 99990%) cell kill leaving only one viable cell. This is a preliminary experience and no final conclusion can be drawn except that it is compatible with the concept that this heroic therapy destroyed 10 to 12 logs of cells. Larger studies are now under way to confirm and extend these observations. As in other studies (Frei et al. 1965) the less the extent of disease, the longer the remission. If the height of the white count is taken as one measure of disease extent, it is interesting to note that one of the two patients had a white count under 10,000 while the other's was 30,000.
There are many other comments that might be added concerning this study, and trials of other drug combinations in the childhood and adult acute leukemias. My sole purpose, however, has been to outline an approach to chemical control of cancer, as illustrated by the studies of Skipper, Frei and other members of the Leukemia Task Force.
From extensive experience with the model and the early experience in the clinic, the working hypothesis is that complete and permanent remission seems possible in acute leukemia of childhood when the cell population is small and when it can be treated vigorously with sufficient drugs to kill all the leukemic cells. A few years ago acute leukemia of childhood was a disease of three to four months (Tivey 1954) . It was not so long ago that a leading article in the Lancet (1964) pointed out that few had survived this disease for more than two years. Quite recently Burchenal (1965) , in a report for the Task Force, had found 101 patients with known acute leukemia who had survived five to fourteen years. Sixty-four of these patients have no sign of the disease. I suspect that these are patients who received chemotherapy at a time when they had small cell populations. Our ability to reproduce these successes is limited by the fact that leukemic cell populations during clinical relapse are probably often above one trillion, while chemotherapy often becomes too toxic when enough is given to kill these numbers of cells. The present studies with drug combinations cannot be extended to the treatment of all leukemic patients at this time. These combinations have been given in a study of a few patients with a quality of patient support not generally available. Toxicity is severe. Combinations of two drugs are, I believe, approaching complete leukemic cell destruction in about I % of leukemic children.
In summary, then, the point of this study of cell kinetics in leukemic mice and children is that for the first time it provides a measure of what proportion of the leukemic cells can be destroyed by drugs. The skilful use of this measure will permit a precise assessment of each new therapy. Every little improvement in management of the leukemic patient brings us a little closer to the goal of complete kill of leukemic cells with less toxicity for the patient. These improvements will come not only from the discovery of new drugs but also from present research on platelet and white cell replacement; on prevention of infection by reverse isolation and better antibiotics for pseudomonas and fungal infections; and especially from better ways of using old antileukemic drugs as their pharmacology, alone and in combination, is understood. Combinations which have a truly synergic effect in vivo are those which show bactericidal synergy in vitro. Bactericidal therapy is of great practical importance in conditions which are inaccessible to the natural defences of the body, or where they are deficient. If in such cases the infecting bacterium is not readily killed by a single drug, then combinations should be tried. There are no absolute rules and double bactericidal sensitivity tests should always be carried out on the infecting strain, but the most likely combination to show this type of synergy is a penicillin and streptomycin.
Drug Combinations in Antibacterial Chemotherapy
If a bactericidal drug is combined with an agent which is only bacteristatic, the killing effect may be antagonized, since many bactericidal drugs only kill rapidly multiplying cells. Again there are no absolute rules, but antagonism is particularly liable to occur when the bactericidal agent is one of the penicillins and is very unlikely to occur when it is a polymyxin, since this kills resting bacteria.
Drug combinations to delay the emergence of drugresistant strains should be considered for infections due to staphylococci and coliform bacilli, particularly in hospitals, and when it is desired to use drugs to which these bacteria readily develop resistance.
Drug combinations may also be the most efficient treatment for mixed infections and may be necessary for the treatment of fulminating infections pending bacteriological diagnosis. The combination of nystatin with a tetracycline may be necessary to prevent candidiasis if tetracycline therapy has to be prolonged.
The use of antibiotic combinations for the treatment of bacterial infections has been the subject of many reviews (Garrod 1953 'Professor Barber died in a road accident on September 11, 1965.
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